Key Highlights
•
A large Japanese study found that lung cancer patients with pre-existing interstitial lung disease (ILD) lived significantly longer when treated with immune checkpoint inhibitors (ICIs) compared to standard chemotherapy, with a median survival of 19.7 months versus 9.9 months. This suggests ICIs offer a substantial survival benefit for this high-risk group, even though they carry a higher risk of drug-induced lung inflammation.
Source →
•
In a mouse model of Alzheimer’s disease, the common sleep medication zolpidem restored healthy sleep patterns, reduced brain amyloid plaque buildup, and improved memory. This research highlights a promising new angle for Alzheimer’s therapy, suggesting that improving sleep quality could directly slow the progression of the disease.
Source →
•
A nationwide study using insurance claims data showed that immune checkpoint inhibitors (ICIs) significantly improved survival for non-small cell lung cancer patients who also had interstitial lung disease, even when used as a first-line treatment. This finding is crucial because it provides real-world evidence supporting the use of these modern drugs in patients who are often excluded from clinical trials due to safety concerns.
Source →
•
Researchers report a rare case of a lung transplant recipient in Georgia, USA, who developed a skin infection caused by the fungus Paraconiothyrium cyclothyrioides. This case is important for doctors as it adds to the list of unusual infections that can threaten patients with weakened immune systems, like transplant recipients, requiring heightened awareness for diagnosis and treatment.
Source →
•
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
